Pajouhan Scientific Journal, Summer, In Press
Back to the articles list |
Back to browse issues page
Ethics code: IR.UMSHA.REC.1401.544
1- School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2- Department of Obstetrics and Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,s.Kamkari@umsha.ac.ir
3- Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
2- Department of Obstetrics and Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,
3- Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract: (50 Views)
Background and Objectives: The COVID-19 pandemic necessitated urgent global vaccination efforts. The Sinopharm COVID-19 vaccine, developed using inactivated virus technology, has been widely used, including pregnant women. The present study aimed to assess the effects of Sinopharm vaccination during pregnancy on neonatal outcomes.
Materials and Methods: This retrospective cohort study was conducted on 236 pregnant women at Fatemiyeh Hospital in Hamadan, Iran, between 2021 and 2022. The study included 118 women who received the Sinopharm COVID-19 vaccine (vaccinated group) and 118 unvaccinated women (unvaccinated group). Neonatal outcomes, including preterm birth, birth weight, Apgar scores, congenital anomalies, and neonatal mortality, were assessed and compared between the two groups.
Results: Baseline characteristics, such as maternal age, body mass index, and parity, were similar between the groups (P>0.05). Neonatal mortality was slightly higher in the vaccinated group (0.8% vs. 0% in the unvaccinated group). Nonetheless, no statistically significant differences were observed in other outcomes, including birth weight, congenital anomalies, or rates of spontaneous abortion.
Conclusion: The Sinopharm COVID-19 vaccine appears to be safe for pregnant women, with no significant increase in the risk of adverse neonatal outcomes. These findings support the use of the Sinopharm vaccine in pregnant women for protection against COVID-19, though further long-term studies are warranted.
Materials and Methods: This retrospective cohort study was conducted on 236 pregnant women at Fatemiyeh Hospital in Hamadan, Iran, between 2021 and 2022. The study included 118 women who received the Sinopharm COVID-19 vaccine (vaccinated group) and 118 unvaccinated women (unvaccinated group). Neonatal outcomes, including preterm birth, birth weight, Apgar scores, congenital anomalies, and neonatal mortality, were assessed and compared between the two groups.
Results: Baseline characteristics, such as maternal age, body mass index, and parity, were similar between the groups (P>0.05). Neonatal mortality was slightly higher in the vaccinated group (0.8% vs. 0% in the unvaccinated group). Nonetheless, no statistically significant differences were observed in other outcomes, including birth weight, congenital anomalies, or rates of spontaneous abortion.
Conclusion: The Sinopharm COVID-19 vaccine appears to be safe for pregnant women, with no significant increase in the risk of adverse neonatal outcomes. These findings support the use of the Sinopharm vaccine in pregnant women for protection against COVID-19, though further long-term studies are warranted.
Type of Study: Research Article |
Subject:
Medicine & Clinical Sciences
Received: 2025/05/20 | Accepted: 2025/06/1
Received: 2025/05/20 | Accepted: 2025/06/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Hamadan University of Medical Sciences.
Published by UMSHA Press
Journal Tel: +98 81 38380090
Publisher Tel: +98 81 38382022
Website: https://psj.umsha.ac.ir/
Email: psj@umsha.ac.ir
